医学
免疫疗法
肺癌
肿瘤科
疾病
耐火材料(行星科学)
内科学
化疗
癌症
临床试验
免疫学
生物
天体生物学
作者
Selina K. Wong,Leora Horn
出处
期刊:The cancer journal
[Ovid Technologies (Wolters Kluwer)]
日期:2020-11-01
卷期号:26 (6): 496-501
被引量:2
标识
DOI:10.1097/ppo.0000000000000482
摘要
Abstract Lung cancer is a leading cause of cancer-related mortality despite continued advances in diagnostic and therapeutic strategies. Although the development of immune checkpoint inhibitors has revolutionized the treatment landscape for advanced non–small cell lung cancer, many patients either have primary resistance to these agents or eventually develop secondary resistance necessitating a change to an alternate therapy. Understanding novel patterns of response to immunotherapy is crucial in determining appropriate selection and sequencing of treatment. Chemotherapy remains the standard of care in immunotherapy-refractory disease, but multiple trials are ongoing to explore the role of combination radioimmunotherapy and rechallenging with immunotherapy either alone or in combination with other antineoplastic agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI